Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2002-10-18
2008-12-09
Haddad, Maher M (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388230, C530S388700
Reexamination Certificate
active
07462696
ABSTRACT:
The invention is composed of monoclonal human MN antibodies or MN antibody fragments that target the GEEDLP (SEQ ID NO: 118) repeat within the proteoglycan domain. The proteoglycan domain of the MN cell surface protein contains four of these identical GEEDLP (SEQ ID NO: 118) repeats. Binding to the desired epitope is verified by competition ELISA, where ELISA signal can be attenuated by co-incubation with a peptide containing this repeat (PGEEDLPGEEDLP (SEQ ID NO: 119)). This inhibition of binding can also be verified using Biacore assays, where binding of desired antibodies to immobilized MN or proteoglycan peptides can be inhibited by the peptide repeat. In addition to binding to the peptide repeat, human anti-MN antibodies can inhibit the cell adhesion of CGL-1 cells to MN coated plastic plates. Human anti-MN antibodies have been used to diagnose and quantify MN expression in cancer cells and tumors using FACS and immunohistochemical methods. An example is also provided where a human anti-MN IgG1 mediates tumor cell lysis though antibody-dependent cell-mediated cytotoxicity. Therefore, these antibodies will be useful for the treatment of cancers in which MN is upregulated or can be useful for the diagnosis of cancers in which MN is upregulated.
REFERENCES:
patent: 6297051 (2001-10-01), Zavada et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 6689744 (2004-02-01), Gao et al.
Panka et al. Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. Proc Natl Acad Sci U S A. 85(9):3080-3084, 1988.
Rudikoff et al Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982 79(6): 1979-83.
Pastorek, J. et al,Oncogene(1994), 9, 2877-2888).
Liao, S.Y., et al,Am J Pathol(1994), 145, 598-609).
Liao, S.Y.,Cancer Res(1997) 57, 2827-2831).
Turner, J.R.Hum Pathol, (1997) 28, 740-744).
Saarnio, J. et al,Am J Pathol(1998) 153, 279-285).
Vermylen, P. et al,Eur Respir J(1999), 14, 806-811).
Chia, S. K. et al,J. Clin. Oncol. (2001) 19, 3660-3668).
Knappik, et al., “Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular consensus Frameworks and CDRs Randomized with Trinucleotides,”J. Mol. Biol.,296: 57-86 (2000).
Xu, et al., “Diversity in the CDR3 Region of VHis Sufficient for Most Antibody Specificities,”Immunity, 13: 37-45 (2000).
Dubois-Stringfellow Nathalie
Murphy John E.
Rinkenberger Julie
Takeuchi Toshihiko
Bayer Pharmaceutical Corporation
Edwards Angell Palmer & & Dodge LLP
Haddad Maher M
Kramer Barry
Loren Ralph
LandOfFree
Human antibodies that have MN binding and cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human antibodies that have MN binding and cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human antibodies that have MN binding and cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4046231